1. Home
  2. SPPL vs ATNM Comparison

SPPL vs ATNM Comparison

Compare SPPL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$3.53

Market Cap

37.0M

Sector

N/A

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.01

Market Cap

33.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPPL
ATNM
Founded
2016
2000
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.0M
33.9M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
SPPL
ATNM
Price
$3.53
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
1.8M
105.6K
Earning Date
04-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.17
EPS
N/A
N/A
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$1.50
$0.95
52 Week High
$7.00
$1.89

Technical Indicators

Market Signals
Indicator
SPPL
ATNM
Relative Strength Index (RSI) 59.49 36.37
Support Level $3.49 $0.99
Resistance Level $4.60 $1.27
Average True Range (ATR) 0.31 0.07
MACD 0.01 -0.02
Stochastic Oscillator 70.32 0.10

Price Performance

Historical Comparison
SPPL
ATNM

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software (Facilities management software). The majority of its revenue is generated from the Robots segment. The company has expanded its operations into Australia /New Zealand and may also enter or expand in other geographic markets such as Canada, Hong Kong, Japan, the Middle East, the United Kingdom, Europe and the United States.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: